Tags

Type your tag names separated by a space and hit enter

Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
Ann Pharmacother. 2015 Sep; 49(9):1046-56.AP

Abstract

OBJECTIVE

To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, tolerability, dosage, and administration of ceftolozane/tazobactam, a new antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor.

DATA SOURCES

A literature search through clinicaltrials.gov and PubMed was conducted (January 2007-May 2015) using the search terms ceftolozane, ceftolozane/tazobactam, FR264205, CXA-101/tazobactam, and CXA-201. References from retrieved articles and abstracts presented at recent meetings were reviewed to identify additional material. The prescribing information was also reviewed.

STUDY SELECTION AND DATA EXTRACTION

Preclinical data as well as phase 1, 2, and 3 studies published in English were evaluated.

DATA SYNTHESIS

Ceftolozane/tazobactam displays enhanced potency against Pseudomonas aeruginosa in vitro. Clinical trials have shown that ceftolozane/tazobactam is noninferior to levofloxacin for the treatment of complicated urinary tract infections (76.9% vs 68.4%, 95% CI = 2.3-14.6) and when used in combination with metronidazole is noninferior to meropenem for the treatment of complicated intra-abdominal infections (83% vs 87.3%, 95% CI = -8.91 to 0.54). An alternate antibiotic should be considered in patients who have a severe β-lactam allergy or an estimated creatinine clearance between 30 and 50 mL/min. Ceftolozane/tazobactam is well tolerated, with few drug interactions and no effects on the cytochrome P450 system.

CONCLUSIONS

In an era of increasing resistance to antimicrobials, ceftolozane/tazobactam provides clinicians with an additional treatment option for infections caused by multidrug-resistant Gram-negative organisms, including extended-spectrum β-lactamase-producing bacteria and Pseudomonas aeruginosa.

Authors+Show Affiliations

Regis University School of Pharmacy, Denver, CO, USA asucher@regis.edu.Palm Beach Atlantic University School of Pharmacy, West Palm Beach, FL, USA.Regis University School of Pharmacy, Denver, CO, USA.Regis University School of Pharmacy, Denver, CO, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26160970

Citation

Sucher, Allana J., et al. "Ceftolozane/Tazobactam: a New Cephalosporin and β-Lactamase Inhibitor Combination." The Annals of Pharmacotherapy, vol. 49, no. 9, 2015, pp. 1046-56.
Sucher AJ, Chahine EB, Cogan P, et al. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination. Ann Pharmacother. 2015;49(9):1046-56.
Sucher, A. J., Chahine, E. B., Cogan, P., & Fete, M. (2015). Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination. The Annals of Pharmacotherapy, 49(9), 1046-56. https://doi.org/10.1177/1060028015593293
Sucher AJ, et al. Ceftolozane/Tazobactam: a New Cephalosporin and β-Lactamase Inhibitor Combination. Ann Pharmacother. 2015;49(9):1046-56. PubMed PMID: 26160970.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination. AU - Sucher,Allana J, AU - Chahine,Elias B, AU - Cogan,Peter, AU - Fete,Matthew, Y1 - 2015/07/09/ PY - 2015/7/11/entrez PY - 2015/7/15/pubmed PY - 2015/12/22/medline KW - antibiotic resistance KW - antibiotics KW - cephalosporins KW - infectious disease KW - β-lactams SP - 1046 EP - 56 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 49 IS - 9 N2 - OBJECTIVE: To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, tolerability, dosage, and administration of ceftolozane/tazobactam, a new antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor. DATA SOURCES: A literature search through clinicaltrials.gov and PubMed was conducted (January 2007-May 2015) using the search terms ceftolozane, ceftolozane/tazobactam, FR264205, CXA-101/tazobactam, and CXA-201. References from retrieved articles and abstracts presented at recent meetings were reviewed to identify additional material. The prescribing information was also reviewed. STUDY SELECTION AND DATA EXTRACTION: Preclinical data as well as phase 1, 2, and 3 studies published in English were evaluated. DATA SYNTHESIS: Ceftolozane/tazobactam displays enhanced potency against Pseudomonas aeruginosa in vitro. Clinical trials have shown that ceftolozane/tazobactam is noninferior to levofloxacin for the treatment of complicated urinary tract infections (76.9% vs 68.4%, 95% CI = 2.3-14.6) and when used in combination with metronidazole is noninferior to meropenem for the treatment of complicated intra-abdominal infections (83% vs 87.3%, 95% CI = -8.91 to 0.54). An alternate antibiotic should be considered in patients who have a severe β-lactam allergy or an estimated creatinine clearance between 30 and 50 mL/min. Ceftolozane/tazobactam is well tolerated, with few drug interactions and no effects on the cytochrome P450 system. CONCLUSIONS: In an era of increasing resistance to antimicrobials, ceftolozane/tazobactam provides clinicians with an additional treatment option for infections caused by multidrug-resistant Gram-negative organisms, including extended-spectrum β-lactamase-producing bacteria and Pseudomonas aeruginosa. SN - 1542-6270 UR - https://www.unboundmedicine.com/medline/citation/26160970/Ceftolozane/Tazobactam:_A_New_Cephalosporin_and_β_Lactamase_Inhibitor_Combination_ L2 - https://journals.sagepub.com/doi/10.1177/1060028015593293?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -